DiaMedica Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business Update August 11, 2022

Rhea-AI Summary

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced it will release its second quarter 2022 financial results on August 10, 2022, after market close. A live conference call is scheduled for August 11, 2022, at 7:00 AM CT to discuss the results and provide a business update. The company is focused on developing novel treatments for neurological disorders and kidney diseases, with its lead candidate, DM199, aimed at treating acute ischemic stroke and chronic kidney disease.

Positive

• Lead candidate DM199 targets treatment of acute ischemic stroke and chronic kidney disease.

Negative

• None.

MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that its second quarter 2022 financial results will be released after the markets close on Wednesday, August 10^th. DiaMedica will host a live conference call on Thursday, August 11^th at 7:00 AM Central Time to provide a business update and discuss financial results.

Conference Call details:

Date:	Thursday, August 11, 2022
Time:	7:00 AM CT / 8:00 AM ET
Web access:	https://events.q4inc.com/attendee/328637791
Dial In:	(888) 440-4368
Conference ID:	4814247

Interested parties may access the conference call by dialing in or listening to the simultaneous webcast. Listeners should log on to the website or dial in 15 minutes prior to the call. The webcast will remain available for play back on our website, under investor relations - events and presentations, following the earnings call and for 12 months thereafter. A telephonic replay of the conference call will be available until August 18, 2022, by dialing (800) 770-2030 (US Toll Free) and entering the replay passcode: 4814247.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant form of the human tissue kallikrein-1 protein (KLK1), an established therapeutic modality for the treatment of acute ischemic stroke and chronic kidney disease. For more information visit our website at www.diamedica.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220804005064/en/

Scott Kellen

Chief Financial Officer

Phone: (763) 496-5118

skellen@diamedica.com

Paul Papi

Corporate Communications

Phone: 617-899-5941

ppapi@diamedica.com

Source: DiaMedica Therapeutics Inc.

FAQ

When will DiaMedica Therapeutics release its Q2 2022 financial results?

DiaMedica Therapeutics will release its Q2 2022 financial results on August 10, 2022.

What time is the DiaMedica Therapeutics conference call?

The conference call is scheduled for August 11, 2022, at 7:00 AM Central Time.

How can I access the DiaMedica Therapeutics earnings call?

Listeners can access the earnings call via a webcast or by dialing in at (888) 440-4368.

What is the focus of DiaMedica Therapeutics?

DiaMedica Therapeutics focuses on developing novel treatments for neurological disorders and kidney diseases.

What is the lead candidate of DiaMedica Therapeutics?

DiaMedica’s lead candidate is DM199, aimed at treating acute ischemic stroke and chronic kidney disease.